The rifamycins: Renewed interest in an old drug class

Progress in Respiratory Research

Volumn 40, Issue , 2011, Pages 18-24

  Burman, William ^a   Dooley, Kelly E ^b   Nuermberger, Eric L ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052920123     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000324212     Document Type: Review

References (47)

1. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S, Tuberculosis Trials Consortium: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial. Lancet 2002;360:528-534.
2. Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, Morris JS, Mitchison DA: Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: Initial report. Am J Respir Crit Care Med 1998;157:1726-1733.
3. Vernon A, Burman W, Benator D, Khan A, Bozeman L: Relapse with rifamycin mono-resistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847. (Pubitemid 29251017)
4. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-341. (Pubitemid 32565595)
5. Zvada SP, van der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM: Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother 2010;54:3390-3394.
6. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D: The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000;157:1575-1580.
7. Hartkoorn RC, Chandler B, Owen A, Ward SA, Bertel Squire S, Back DJ, Khoo SH: Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of Pglycoprotein. Tuberculosis (Edinb) 2007;87:248-255. (Pubitemid 46551848)
8. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002;36:164-172. (Pubitemid 34700774)
9. Smith NF, Figg WD, Sparreboom A: Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429-445.
10. Loos U, Musch E, Jensen JC, Mikus G, Schwabe JK, Eichelbaum M: Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985;63:1205-1211. (Pubitemid 16169743)
11. Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, Dorman SE: Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008;52:4037-4042.
12. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, MacKenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A: Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010;54:4192-4200.
13. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S: Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during onceweekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-1197. (Pubitemid 38680395)
14. Weiner M, Benator D, Burman W, Peloquin C, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T, Tuberculosis Trials Consortium: The association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with tuberculosis and HIV. Clin Infect Dis 2005;40:1481-1491. (Pubitemid 40628637)
15. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P: Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50:1170-1177.
16. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, Moffat HJ, Peloquin CA: Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005;41:461-469. (Pubitemid 41099637)
17. Peloquin D, Weiner M, Engle M, Johnson J, Nsubuga P, Bliven E, Padayatchi N, Mthethwa T, MacKenzie W: Pharmacokinetics of rifapentine in TB patients receiving 600 mg daily. 3rd Int Workshop Clin Pharmacol Tuberculosis Drugs, Boston, 2010.
18. Chiqutsa E, Visser M, Egan D, Holford N, Smith P, Owen A, McIlleron H: Population pharmacokinetics of rifampicin in South African tuberculosis patients and the influence of drug transporter polymorphisms. 3rd Int Workshop Clin Pharmacol Tuberculosis Drugs, Boston, 2010.
19. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PR: Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 2008;5:e176.
20. Treatment of tuberculosis: Guidelines for national programmes, ed 3. Geneva, World Health Organization, 2003.
21. Schaaf HS, Willemse M, Cilliers K, Labadarios D, Maritz JS, Hussey GD, McIlleron H, Smith P, Donald PR: Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 2009;7:19.
22. Peloquin CA: Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87. (Pubitemid 27152505)
23. Blake MJ, Abdel-Rahman SM, Jacobs RF, Lowery NK, Sterling TR, Kearns GL: Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J 2006;25:405-409.
24. Weiner M, Wing D, Burman W, Peloquin C, Engle M, Prihoda T, MacKenzie W, Bliven E, Benator D, Weis S, Sterling T, Villarino E: Rifapentine pharmacokinetics in children and adults receiving once-weekly rifapentine and isoniazid for the treatment of latent tuberculosis infection. 39th World Conf Lung Health, Paris, October 2008.
25. Long MW, Snider DEJ, Farer LS: US Public Health Service trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-894. (Pubitemid 9208241)
26. Jeanes CWL, Jessamine AG, Eidus L: Treatment of chronic drug-resistant pulmonary tuberculosis with rifampin and ethambutol. Can Med Assoc J 1972;106:884-888.
27. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5(suppl 3):S440-S445.
28. Kreis B, Pretet S, Birenbaum J, Guibout P, Hazeman JJ, Orin E, Perdrizet S, Weil J: Two threemonth treatment regimens for pulmonary tuberculosis. Bull Int Union Against Tuberc 1976;51:71-75.
29. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL: Concentrationdependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788. (Pubitemid 350057771)
30. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V: Pharmacokinetics- pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124. (Pubitemid 36753560)
31. Jindani A, Baer VR, Edwards EA, Mitchison DA: The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-949. (Pubitemid 10118376)
32. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR: Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51:2994-2996. (Pubitemid 47206244)
33. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA: The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-135. (Pubitemid 40923325)
34. Grosset J, Rosenthal I, Zhang E, Nuermberger E: Dose-ranging comparison of rifampin and rifapentine in combination with isoniazid and pyrazinamide in the mouse model of tuberculosis. 48th Annu Intersci Conf Antimicrob Agents Chemother, Washington, 2008.
35. Peloquin C: What is the 'right' dose of rifampin? Int J Tuberc Lung Dis 2003;7:3-5. (Pubitemid 36427025)
36. Heifets LB, Lindhom-Levy P, Flory MA: Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:626-630. (Pubitemid 20109150)
37. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL: Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
38. Langdon G, Wilkins J, McFadyen L, McIlleron H, Smith P, Simonsson US: Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob Agents Chemother 2005;49:4429-4436. (Pubitemid 41552569)
39. Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, Mosher A, Samuels M, Vernon A: A prospective, randomized, doubleblind study of the tolerability of rifapentine 600, 900 and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002;165:1526-1530. (Pubitemid 34606668)
40. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL: Potent twice-weekly rifapentinecontaining regimens in murine tuberculosis. Am J Respir Crit Care Med 2006;174:94-101. (Pubitemid 43955249)
41. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US: Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008;52:2138-2148. (Pubitemid 351758551)
42. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T: Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003;167:1341-1347. (Pubitemid 36609717)
43. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR: An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952. (Pubitemid 44564795)
44. Burman WJ, Gallicano K, Peloquin C: Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clin Infect Dis 1999;28:419-430. (Pubitemid 29242513)
45. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G: Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008;300:530-539.
46. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
47. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE: Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338. (Pubitemid 44156613)